Imagion Biosystems (ASX:IBX) said its contract manufacturer completed production of MagSense, its HER2 breast cancer imaging agent, and is now completing the required analytical testing for use in its phase 2 clinical study, according to a Tuesday filing with the Australian bourse.
The company also said the US federal government shutdown will not impact its phase 2 clinical trial investigational new drug application submission.
Shares of the company rose 6% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.